logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Precursor Tcell Lymphoblastic Leukemialymphoma

    FiltersReset Filters
    7 results

    • dasatinib

      (Dasatinib)
      Dr. Reddy's Laboratories Inc.
      Usage: Dasatinib tablets are indicated for adults with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) and those with advanced Ph+ CML or Ph+ acute lymphoblastic leukemia (ALL) who are resistant or intolerant to prior therapy. They are also approved for pediatric patients with Ph+ CML and newly diagnosed Ph+ ALL.

    • dasatinib

      (dasatinib)
      Biocon Pharma Inc.
      Usage: Dasatinib is indicated for treating adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (CML) in chronic phase, Ph+ CML with resistance to prior therapy, and Ph+ acute lymphoblastic leukemia (ALL). It is also indicated for pediatric patients aged 1 and older with Ph+ CML and newly diagnosed Ph+ ALL.

    • dasatinib

      (dasatinib)
      Prasco Laboratories
      Usage: Dasatinib tablets are indicated for adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (CML), Ph+ CML with resistance/intolerance to prior therapy, and Ph+ acute lymphoblastic leukemia (ALL). They are also indicated for pediatric patients (≥1 year) with Ph+ CML and newly diagnosed Ph+ ALL with chemotherapy.

    • doxorubicin hydrochloride

      (DOXORUBICIN HYDROCHLORIDE)
      Fresenius Kabi USA, LLC
      Usage: Doxorubicin Hydrochloride Injection is indicated for treating various cancers, including leukemias, Wilms' tumor, neuroblastoma, sarcomas, and several carcinomas. It is also used as adjuvant therapy for women with axillary lymph node involvement post-primary breast cancer resection.

    • nelarabine

      (Nelarabine)
      XGen Pharmaceuticals DJB, Inc.
      Usage: Nelarabine injection is indicated for treating T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adults and children aged 1 year and older, specifically when the disease has not responded to or has relapsed after at least two chemotherapy regimens.

    • nelarabine

      (Nelarabine)
      Zydus Pharmaceuticals USA Inc.
      Usage: Nelarabine Injection is indicated for treating T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adults and pediatric patients aged 1 year and older who have not responded to or have relapsed after at least two chemotherapy regimens.

    • nelarabine

      (Nelarabine)
      Gland Pharma Limited
      Usage: Nelarabine is indicated for treating T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in patients aged 1 year and older, specifically when the disease has not responded to or has relapsed after at least two chemotherapy regimens.